Trojan-Horse Weight-Loss Molecule Delivers Potent Results in Mice

Scientists at Helmholtz Munich created a hybrid 'Trojan horse' drug that uses GLP-1R/GIPR signaling as an entry door and carries lanifibranor to activate PPARα/γ/δ inside cells, hitting five targets. In diet-induced obese mice, it reduced appetite, produced greater weight loss, and improved blood glucose versus reference therapies, with GI side effects similar to current incretin medicines. The approach is preclinical; whether results translate to humans remains to be seen and will require clinical development.